News
IBIO
1.900
+6.74%
0.120
Weekly Report: what happened at IBIO last week (0415-0419)?
Weekly Report · 1d ago
iBio files to sell 10.57M shares of common stock for holders
Seeking Alpha · 04/16 20:20
IBIO INC -FILES PROSPECTUS RELATES TO RESALE FROM TIME TO TIME OF UP TO 10.6 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS
Reuters · 04/16 20:13
Weekly Report: what happened at IBIO last week (0408-0412)?
Weekly Report · 04/15 09:39
Weekly Report: what happened at IBIO last week (0401-0405)?
Weekly Report · 04/08 09:41
HUT, CXAI and BDRX among pre-market losers
HUT, CXAI and BDRX among pre-market losers. Acorda Therapeutics files for Chapter 11 bankruptcy. Canoo reports mixed Q4 results. Humana, Hut 8 Corp, and iBio among other companies downgraded. Bitcoin production slips.
Seeking Alpha · 04/02 12:37
iBio Inc. Raises $15M in Private Placement and Issues Warrants
TipRanks · 04/01 20:53
BUZZ-U.S. STOCKS ON THE MOVE-Trump Media & Technology, Semtech, General Dynamics
The tech-heavy Nasdaq outpaced Wall Street peers on Monday as megacap growth stocks gained on hopes of an early rate cut by the Fed. The Dow Jones Industrial Average was down 0.63% at 39,555.06. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 15:50
Weekly Report: what happened at IBIO last week (0325-0329)?
Weekly Report · 04/01 09:41
12 Health Care Stocks Moving In Friday's Pre-Market Session
Avalo Therapeutics stock rose 289.1% to $18.48 during Friday's pre-market session. Xilio Therapeutic (XLO) shares moved upwards by 205.16% during the session. Biodexa Pharmaceuticals (BDRX) shares also moved upwards. Losers NuCana (NCNA) and Yield10 Bioscience (YTEN) fell in the pre- market session.
Benzinga · 03/29 12:06
iBio, Mesoblast, Kodiak Sciences among healthcare movers
IBio, Mesoblast, Kodiak Sciences among healthcare movers. S&P 500 Health Care Sector +0.18% to 1725.9. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. S&p 500 Healthcare Equipment & Services among healthcare mover.
Seeking Alpha · 03/28 14:01
SMR, GCTS and GSIW among mid-day movers
On the Move SMR, GCTS and GSIW among mid-day movers. GCT Semiconductor Holding (GCTS) and iBio are among the biggest gainers in the SA market. SMR and GCSR among the largest losers.
Seeking Alpha · 03/27 17:22
iBio climbs after AI-led drug discovery deal
IBio, Inc. Shares more than doubled on Thursday. The biotech announced a collaboration with privately held AstralBio to develop drugs for obesity and other cardiometabolic conditions. IBIO will leverage its AI/machine learning platform to develop the drugs. The deal is funded by a $15M private placement.
Seeking Alpha · 03/27 16:00
Canada Goose Layoffs 2024: What to Know About the Latest GOOS Job Cuts
Canada Goose stock is up 5% as of Wednesday morning. The luxury clothing company announced job cuts for its corporate headquarters. The layoffs are part of the company's Transformation Plan. Rent the Runway stock, iBio shares and Xpeng stock are all up on Wednesday.
Investorplace · 03/27 14:37
RENT Stock Alert: Rent the Runway Preps for a 1-for-20 Reverse Stock Split
Rent the Runway stock will undergo a one-for-20 reverse stock split on April 2. The designer closet company is going to consolidate 20 shares of RENT stock into a single share. The company is enacting the reverse split to increase the price of its shares. IBio, Xpeng and Hannover Rueck stock are all moving Wednesday.
Investorplace · 03/27 14:20
iBio Shares Double After Collaboration Agreement With AstralBio
IBio shares doubled after the company entered into a collaboration agreement with AstralBio to develop novel antibodies to treat obesity and other cardiometabolic conditions. IBio closed a $15 million private placement financing on Tuesday. The stock hit its 52-week low of $1.02 and is down 95% in the past year.
Dow Jones · 03/27 14:08
Why Is iBio (IBIO) Stock Up 125% Today?
IBio is partnering with AstralBio to develop “novel antibodies.” The antibodies may eventually become treatments for cardiometabolic diseases, including obesity. IBio raised $15 million in a private placement yesterday. The company generated no revenue in its last fiscal year.
Investorplace · 03/27 14:04
Micro-Cap Stock iBio Doubles On Wednesday - Here's Why
IBio Inc (NYSE:IBIO) shares are surging after the company entered into a collaboration agreement with AstralBio Inc. To develop antibodies to treat obesity and other cardiometabolic conditions. The shares are trading over 100% with a strong session volume of 38.98 million. This micro-cap biotech player is valued at $4 million, with an enterprise value of $17.7 million.
Benzinga · 03/27 14:04
iBio, ImmunityBio, Mesoblast among healthcare movers
IBio, ImmunityBio, Mesoblast among healthcare movers. S&P 500 Health Care Sector +1.04% to 1717.5. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index. IBio, immunityBio, mesoblast are among the biggest gainers.
Seeking Alpha · 03/27 14:00
Market-Moving News for March 27th
IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases. Direct Digital Holdings shares are lower after reporting worse-than-expected Q4 financial results. Novocure shares are higher after company's lung cancer trial met primary endpoint.
Benzinga · 03/27 12:31
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.